Yudai Shimojukkoku | Oncology | Best Researcher Award

Published on by Best Achievements

Dr. Yudai Shimojukkoku | Oncology | Best Researcher Award

Dr. Yudai Shimojukkoku, Saitama Cancer Center, Japan.

Dr. Shimojukkoku Yudai 🧑‍🔬 is a dedicated cancer researcher at Saitama Cancer Center and Kagoshima University. His work focuses on oral squamous cell carcinoma, exploring the tumor microenvironment and identifying novel biomarkers 🧫. He collaborates with renowned experts like Prof. Sasahira, advancing both basic and clinical research. His contributions aim to bridge the gap between oral health and systemic diseases such as diabetes 🦷❤️. Dr. Yudai’s research is paving the way for innovative cancer diagnostics and treatments. 🌟

Profile

SCOPUS ID

🎓 Early Academic Pursuits

Dr. Shimojukkoku Yudai embarked on his academic journey with a deep-rooted passion for medical sciences, particularly in oncology. He demonstrated an early commitment to understanding the biological mechanisms of cancer, eventually focusing his expertise on oral squamous cell carcinoma. His educational background provided a strong foundation in both clinical and molecular pathology, setting the stage for a career centered on bridging lab-based discoveries with real-world clinical applications.

💼 Professional Endeavors

Currently affiliated with the Saitama Cancer Center and Kagoshima University’s Department of Molecular and Oral Pathology, Dr. Yudai combines research with clinical responsibilities. He is deeply involved in improving diagnostic techniques and therapeutic approaches in oral cancer. His daily work integrates patient-centered care with experimental exploration, ensuring translational relevance of his research.

🔬 Contributions and Research Focus On Oncology 

Dr. Yudai’s research targets the tumor microenvironment and identification of novel biomarkers in oral cancer. He has led and participated in both in vitro and in vivo studies, as well as computational analyses (in silico) to discover two previously unidentified markers that have since influenced ongoing investigative studies. His active collaboration with renowned cancer researcher Prof. Sasahira has further enhanced his research on the link between oral cancer and periodontal disease, and the complex relationship between cancer progression and diabetes mellitus.

🌍 Impact and Influence

Although early in his career, Dr. Yudai’s work has begun to leave a significant impact in the field of oral oncology. His insights are contributing to the evolving understanding of how systemic diseases and oral cancer interact. His research, while currently limited in citation due to its recent publication, presents promising implications for clinical diagnostics and personalized cancer therapy. His focus on translational outcomes ensures his findings are poised to improve patient outcomes in the near future.

🧠 Research Skills

Dr. Yudai demonstrates a versatile skill set encompassing molecular biology, histopathology, bioinformatics, and clinical oncology. He is adept at designing and executing comprehensive experimental workflows and data interpretation. His capacity to blend clinical insights with molecular discoveries makes him a valuable asset in precision medicine research.

🏅 Awards and Honors

Dr. Yudai is actively seeking recognition in categories such as the Young Scientist Award, Best Researcher Award, Outstanding Scientist Award, and Best Research Scholar Award. His self-motivated dedication, impactful publications, and meaningful collaborations make him a strong contender for these accolades. His contributions signify excellence in early-stage cancer research.

🏛️ Legacy and Future Contributions

As he advances, Dr. Yudai aims to pioneer new diagnostic tools and therapeutic targets that can revolutionize the treatment of oral cancers. His collaborative spirit and interdisciplinary research vision promise continued contributions to global cancer research. With a commitment to both innovation and patient care, he is laying a foundation that could influence generations of oncological practice and research.

Publications Top Notes

📘 Title: MCTP2 is a novel biomarker promoting tumor progression and nodal metastasis in oral squamous cell carcinoma
🧑‍🔬 Authors: Shimojukkoku Yudai, et al.
📚 Journal: Scientific Reports
📅 Year: 2025
🔗 Link: https://www.nature.com/articles/s41598-025-02094-9 (🔒 Currently disabled)
🧬 Highlights: Introduces MCTP2 as a promising biomarker for tumor progression and nodal metastasis in oral squamous cell carcinoma.

 

Yvonne Rosenberg | Cancer | Best Researcher Award

Published on by Best Achievements

Dr. Yvonne Rosenberg | Cancer | Best Researcher Award

Dr. Yvonne Rosenberg,PlantVax Inc, United States.

🌿 Dr. Yvonne J. Rosenberg is the CEO of PlantVax Inc. and a leading expert in immunology and biotherapeutic innovation. With a Ph.D. from Australian National University, she has pioneered research in HIV immunotherapy, autoimmunity, and nerve agent antidotes. 🌍 Her work bridges basic science and translational medicine, using plant-based systems to produce cutting-edge therapies. 💉 With decades of global recognition and impactful publications, she continues to revolutionize the field of biomedical science. 🧬

Profile

Scopus profile

Orcid Profile

🎓 Early Academic Pursuits

Yvonne J. Rosenberg began her academic journey at the University of Queensland, Australia, earning a B.Sc. in Zoology (1969) and a First-Class Honours B.Sc. in Parasitology (1970). She continued to develop her scientific expertise with a Ph.D. in Immunology from Australian National University in 1976. Her foundational academic training provided a robust framework in parasitology and immunological mechanisms. Rosenberg further honed her expertise as a Visiting Fellow at the National Institutes of Health (NIH), where she focused on advanced immunological research. 🎓🔬

💼 Professional Endeavors

Dr. Rosenberg’s professional journey spans academia, industry, and biotech leadership. From her early roles as a Visiting Scientist in London to research positions at NIH and Columbia University, she moved into leadership roles at TherImmune Research Corp and ProCell Corporation. In 2007, she founded PlantVax Inc, where she currently serves as CEO. Her work reflects a seamless blend of translational research and product innovation across fields such as HIV, autoimmune disease, and biodefense. 🏢🌿

🔬 Contributions and Research Focus On Cancer 

Dr. Rosenberg’s research contributions are vast and groundbreaking. Her early work on B lymphocyte development and T cell regulation laid the groundwork for major advancements in immunology and parasitology. She transitioned into HIV pathogenesis research, utilizing macaque models to study immune responses. More recently, her focus has shifted to the development of recombinant therapeutic molecules, including broadly neutralizing HIV antibodies (bnAbs) and plant-derived cholinesterases for neurotoxin defense. 🌱🧪

🌍 Impact and Influence

Dr. Rosenberg’s research has directly impacted fields ranging from infectious diseases to neuroprotection, influencing therapeutic approaches and policy directions in HIV, autoimmunity, and biodefense. Her innovative plant-based expression systems offer cost-effective solutions with global health applications, making her work especially relevant in low-resource settings. Her translational focus has brought lab innovations closer to real-world implementation. 💡🌐

🧠 Research Skills

Dr. Rosenberg possesses expertise in molecular immunology, plant-based protein expression, animal modeling, vaccine development, and biochemical pharmacology. Her ability to translate basic research into applied therapies demonstrates her proficiency in both exploratory science and product development. Her skills extend to leadership in collaborative, interdisciplinary research initiatives. 🧬🧫

🏅 Awards and Honors

Dr. Rosenberg’s exceptional achievements have been recognized with numerous awards, including the NIH Fogarty Award, NHMRC CJ Martin Biomedical Award, and American Association of Immunologists Travel Awards. These accolades underscore her influence and sustained contributions to biomedical research at the global level. 🥇🌟

🏛️ Legacy and Future Contributions

With a career spanning decades, Dr. Rosenberg’s legacy lies in her interdisciplinary approach—blending basic immunology with translational innovation. Her pioneering use of plant systems for protein production is likely to shape the future of vaccine and therapeutic development. As she continues her leadership at PlantVax, her work promises to drive forward solutions for HIV prevention, autoimmune treatment, and chemical threat mitigation. Her contributions will resonate through both scientific literature and lifesaving applications for years to come. 🚀🌿

Publications Top Notes

📄 1. A single post-exposure oxime RS194B treatment rapidly reactivates acetylcholinesterase and reverses acute symptoms in macaques exposed to diethylphosphorothioate parathion and chlorpyrifos insecticides
📰 Journal: Journal of Neurochemistry
📅 Year: 2024
🔢 Citations: 4
🧪 Topic: Organophosphate poisoning, macaque model, oxime therapy

📄 2. The impact of solvents on the toxicity of the banned parathion insecticide
📰 Journal: Chemico-Biological Interactions
📅 Year: 2023
🔢 Citations: 3
🧪 Topic: Parathion insecticide, solvent effects, toxicology

📄 3. Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
📰 Journal: mBio
📅 Year: 2023
🔢 Citations: 8
🧬 Topic: Immunoglobulin transport, placental biology, Fc receptors

Nazia chaudhary | Cancer Biology | Best Researcher Award

Published on by Best Achievements

Dr. Nazia chaudhary | Cancer Biology | Best Researcher Award

Dr. Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, recognized for her groundbreaking work in cancer research. She earned her Ph.D. in 2022 from ACTREC (HBNI) and holds an M.Sc. from St. Xavier’s College, Mumbai. Her research focuses on tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities, with significant contributions to colorectal and breast cancer studies. Dr. Chaudhary has co-authored numerous high-impact publications and holds patents on therapeutic antibodies. She has presented her work at prestigious conferences globally and received accolades, including the DST Inspire Faculty Award and recognition for excellence in biological sciences.

Author Profile:

🎓 Education:

Dr. Nazia S. Chaudhary holds a Ph.D. in Cancer Biology from ACTREC (Homi Bhabha National Institute), which she completed in 2022. Her doctoral research explored critical aspects of tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities in cancer. Prior to her Ph.D., she earned her M.Sc. in Life Sciences from St. Xavier’s College, Mumbai, where she developed a strong foundation in molecular and cellular biology. Dr. Chaudhary’s academic journey has been marked by exceptional performance, laying the groundwork for her impactful research career. Her educational achievements reflect her dedication to advancing scientific knowledge in cancer biology and therapeutic innovation.

💼 Professional Experience:

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, where she leads innovative research in cancer biology. She completed her Ph.D. in 2022 from ACTREC (HBNI), focusing on tumorigenesis and therapeutic resistance mechanisms. Dr. Chaudhary has extensive experience in identifying chemo-radio resistance pathways and exploring therapeutic vulnerabilities in colorectal and breast cancers. Her professional expertise spans molecular oncology, antibody development, and translational research, leading to impactful publications and patents. She has presented her findings at leading international conferences and collaborates with multidisciplinary teams to advance cancer therapeutics. Her work has earned her prestigious awards and recognition.

🌍Research Contributions:

Dr. Nazia S. Chaudhary has made significant contributions to cancer research, particularly in understanding tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities. Her work has advanced knowledge of colorectal and breast cancers, identifying novel molecular mechanisms that drive cancer progression and resistance to therapies. She has co-authored numerous high-impact publications in reputed journals, showcasing her innovative findings. Dr. Chaudhary’s research has led to patents on therapeutic antibodies, offering potential breakthroughs in targeted cancer treatments. Her contributions have been presented at renowned international conferences, reflecting her commitment to advancing cancer biology and developing effective therapeutic strategies for improved patient outcomes.

🥇Award and Honors:

Dr. Nazia S. Chaudhary has received numerous awards and honors for her outstanding contributions to cancer research. She was honored with the prestigious DST Inspire Faculty Award for her innovative work in tumor biology and therapeutic strategies. Her exceptional research has earned recognition at national and international platforms, including accolades for excellence in biological sciences. Dr. Chaudhary’s groundbreaking discoveries in chemo-radio resistance and therapeutic vulnerabilities have been acknowledged through awards at esteemed conferences and institutions. She also holds patents for therapeutic antibodies, reflecting her pioneering contributions to cancer therapeutics and her commitment to advancing translational research.

Conclusion:

Dr. Nazia S. Chaudhary’s exemplary contributions to cancer research have advanced our understanding of tumor biology, therapeutic resistance, and targeted interventions. Her innovative work on colorectal and breast cancer, coupled with her patents on therapeutic antibodies, highlights her dedication to developing effective treatment strategies. With a strong publication record and international recognition, Dr. Chaudhary continues to push the boundaries of cancer research, addressing critical challenges in oncology. Her achievements serve as a testament to her scientific excellence, making her a leading figure in the field and inspiring future advancements in cancer therapeutics and precision medicine.

📚Publication Top Notes:

Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer
International Journal of Cancer 149(7), 1495-1511, 135 citations, 2021 📈🧬

Plakophilin3 loss leads to an increase in lipocalin2 expression, which is required for tumour formation
Experimental Cell Research 369(2), 251-265, 25 citations, 2018 🔬🧪

Thermophilic actinomycetes from hot water spring capable of producing enzymes of industrial importance
Int J Res Stud Biosci 4, 29-35, 15 citations, 2016 🌿🌡️

Tumor-specific overexpression of histone gene, H3C14 in gastric cancer is mediated through EGFR-FOXC1 axis
Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1864(4-5), 2021, 14 citations 🔬🧬

Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
FEBS Letters 597(8), 1086-1097, 4 citations, 2023 ⚡🔬

Spatial Epidemiology of Signet-ring Cell Colorectal Cancer in India
Saudi Journal of Medicine & Medical Sciences 12(1), 71-75, 3 citations, 2024 🌍📊

Plakophilin3 loss leads to an increase in autophagy and radio-resistance
Biochemical and Biophysical Research Communications 620, 1-7, 3 citations, 2022 🔄📉

LCN2 and colon cancer—Have we hit the jackpot.
Journal of Clinical Oncology 38(15_suppl), e15608-e15608, 2 citations, 2020 🎯🔬

Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome
Journal of Oral Pathology & Medicine 52(9), 849-859, 1 citation, 2023 🦷🦠

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
bioRxiv, 2023.07.17.549374, 1 citation, 2023 🔬⚡

GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
bioRxiv, 2023.05.18.541287, 1 citation, 2023 🔬🔑